company background image
NVAX logo

Novavax NasdaqGS:NVAX Stock Report

Last Price

US$7.92

Market Cap

US$1.3b

7D

3.1%

1Y

56.5%

Updated

11 Mar, 2025

Data

Company Financials +

NVAX Stock Overview

A biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. More details

NVAX fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

My Notes

Capture your thoughts, links and company narrative

Novavax, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Novavax
Historical stock prices
Current Share PriceUS$7.92
52 Week HighUS$23.86
52 Week LowUS$3.81
Beta2.91
1 Month Change-2.58%
3 Month Change-10.20%
1 Year Change56.52%
3 Year Change-89.27%
5 Year Change-16.63%
Change since IPO-90.10%

Recent News & Updates

Recent updates

Novavax Cashes In On Its COVID Albatross -- Challenges Remain (Rating Upgrade)

Jan 16

Novavax, Inc. (NASDAQ:NVAX) Shares Fly 26% But Investors Aren't Buying For Growth

Dec 17
Novavax, Inc. (NASDAQ:NVAX) Shares Fly 26% But Investors Aren't Buying For Growth

Novavax, Inc. (NASDAQ:NVAX) Just Reported, And Analysts Assigned A US$16.67 Price Target

Nov 15
Novavax, Inc. (NASDAQ:NVAX) Just Reported, And Analysts Assigned A US$16.67 Price Target

Novavax Q3 Earnings Disappoint, But A Turnaround May Be Underway

Nov 13

Novavax, Inc.'s (NASDAQ:NVAX) 35% Dip In Price Shows Sentiment Is Matching Revenues

Nov 01
Novavax, Inc.'s (NASDAQ:NVAX) 35% Dip In Price Shows Sentiment Is Matching Revenues

Novavax Q3 Earnings A Week Away - Time To Accept A New Reality

Oct 31

Novavax's Future Hinges On Sanofi Deal And Upcoming Milestones

Sep 01

Novavax, Inc.'s (NASDAQ:NVAX) Shares Lagging The Industry But So Is The Business

Aug 14
Novavax, Inc.'s (NASDAQ:NVAX) Shares Lagging The Industry But So Is The Business

Novavax: Staying Long Despite Coming Up Short In Q2

Aug 13

Novavax Ahead Of Q2 Earnings - Picking Apart The Sanofi Deal

Jul 26

Novavax: New Chapter, Questions Remain

Jun 20

Novavax, Inc. (NASDAQ:NVAX) Surges 206% Yet Its Low P/S Is No Reason For Excitement

May 14
Novavax, Inc. (NASDAQ:NVAX) Surges 206% Yet Its Low P/S Is No Reason For Excitement

Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 13
Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely

May 07

Novavax: Another Day Older And Deeper In

Mar 02

Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry

Mar 02
Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry

Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00

Mar 01
Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00

Novavax Q4 Earnings Preview: Settlement With Gavi Doesn't Solve Problems

Feb 23

Investors Don't See Light At End Of Novavax, Inc.'s (NASDAQ:NVAX) Tunnel

Sep 06
Investors Don't See Light At End Of Novavax, Inc.'s (NASDAQ:NVAX) Tunnel

Shareholder Returns

NVAXUS BiotechsUS Market
7D3.1%1.2%-4.6%
1Y56.5%-6.7%8.8%

Return vs Industry: NVAX exceeded the US Biotechs industry which returned -6.7% over the past year.

Return vs Market: NVAX exceeded the US Market which returned 8.8% over the past year.

Price Volatility

Is NVAX's price volatile compared to industry and market?
NVAX volatility
NVAX Average Weekly Movement10.6%
Biotechs Industry Average Movement10.8%
Market Average Movement6.3%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market3.3%

Stable Share Price: NVAX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: NVAX's weekly volatility has decreased from 20% to 11% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1987952John Jacobsglobal.novavax.com

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications.

Novavax, Inc. Fundamentals Summary

How do Novavax's earnings and revenue compare to its market cap?
NVAX fundamental statistics
Market capUS$1.32b
Earnings (TTM)-US$187.50m
Revenue (TTM)US$682.16m

1.9x

P/S Ratio

-6.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NVAX income statement (TTM)
RevenueUS$682.16m
Cost of RevenueUS$569.64m
Gross ProfitUS$112.52m
Other ExpensesUS$300.02m
Earnings-US$187.50m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.17
Gross Margin16.49%
Net Profit Margin-27.49%
Debt/Equity Ratio-27.2%

How did NVAX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/11 21:34
End of Day Share Price 2025/03/11 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novavax, Inc. is covered by 26 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
George ZavoicoB. Riley Securities, Inc.
Mayank MamtaniB. Riley Securities, Inc.